$52.82
Insights on Arcellx, Inc.
In the last 1 year, Novo Nordisk A/s has given 52.6% return, outperforming this stock by 19.8%
0.53%
Downside
Day's Volatility :4.37%
Upside
3.86%
41.8%
Downside
52 Weeks Volatility :59.07%
Upside
29.67%
Period | Arcellx, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -8.26% | 2.0% | 0.0% |
6 Months | 68.18% | 11.7% | 0.0% |
1 Year | 32.78% | 5.8% | 1.3% |
3 Years | 224.05% | 14.2% | -22.1% |
Market Capitalization | 2.8B |
Book Value | $9.28 |
Earnings Per Share (EPS) | -1.47 |
Wall Street Target Price | 80.31 |
Profit Margin | -64.08% |
Operating Margin TTM | 23.75% |
Return On Assets TTM | -9.86% |
Return On Equity TTM | -20.48% |
Revenue TTM | 110.3M |
Revenue Per Share TTM | 2.3 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -87.8M |
Diluted Eps TTM | -1.47 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.94 |
EPS Estimate Next Year | -2.01 |
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Next Quarter | -0.59 |
What analysts predicted
Upside of 52.04%
Sell
Neutral
Buy
Arcellx, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Arcellx, Inc. | -20.91% | 68.18% | 32.78% | 224.05% | 224.05% |
Moderna, Inc. | -2.26% | 35.27% | -21.9% | -39.25% | 318.83% |
Regeneron Pharmaceuticals, Inc. | -5.59% | 12.81% | 13.84% | 81.04% | 166.5% |
Novo Nordisk A/s | -0.32% | 31.91% | 50.92% | 247.21% | 431.9% |
Vertex Pharmaceuticals Incorporated | -2.67% | 11.53% | 21.99% | 86.62% | 131.89% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Arcellx, Inc. | NA | NA | NA | -1.94 | -0.2 | -0.1 | NA | 9.28 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.22 | -0.29 | -0.12 | NA | 36.27 |
Regeneron Pharmaceuticals, Inc. | 25.9 | 25.9 | 1.46 | 45.02 | 0.16 | 0.08 | NA | 242.47 |
Novo Nordisk A/s | 47.09 | 47.09 | 2.4 | 3.33 | 0.88 | 0.23 | 0.01 | 23.9 |
Vertex Pharmaceuticals Incorporated | 28.81 | 28.81 | 0.53 | 16.76 | 0.23 | 0.13 | NA | 68.22 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Arcellx, Inc. | Buy | $2.8B | 224.05% | NA | -64.08% |
Moderna, Inc. | Buy | $40.0B | 318.83% | 24.73 | -68.84% |
Regeneron Pharmaceuticals, Inc. | Buy | $98.8B | 166.5% | 25.9 | 30.14% |
Novo Nordisk A/s | Buy | $558.9B | 431.9% | 47.09 | 36.03% |
Vertex Pharmaceuticals Incorporated | Buy | $103.4B | 131.89% | 28.81 | 36.68% |
Perceptive Advisors LLC
FMR Inc
NEA Management Company, LLC
Paradigm Biocapital Advisors LP
SR ONE CAPITAL MANAGEMENT, LP
BlackRock Inc
Arcellx, Inc.’s price-to-earnings ratio stands at None
Read MoreArcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.
Organization | Arcellx, Inc. |
Employees | 130 |
CEO | Mr. Rami Elghandour |
Industry | Healthcare |
Tenet Healthcare Corp.
$52.82
-2.98%
Surgery Partners Inc
$52.82
-2.98%
Amn Healthcare Services Inc.
$52.82
-2.98%
Penumbra Inc
$52.82
-2.98%
Option Care Health Inc
$52.82
-2.98%
Corcept Therapeutics Inc
$52.82
-2.98%
Vaxcyte Inc
$52.82
-2.98%
Hutchison China Meditech Limited
$52.82
-2.98%
Xenon Pharmaceuticals Inc
$52.82
-2.98%